DG
8
-2
EBAY
42
-2
HAL
48
-3
PG
50
2
URBN
48
-6
ORLY
60
-5
SJM
9
-5
F
56
-3
AMT
37
3
ED
45
3
EMR
71
-3
PBI
56
-2
CMG
66
-4
HCP
56
-8
SBUX
37
-2
MRO
50
4
TGNA
50
-6
DFS
64
2
ETN
75
-3
CHD
54
4
DG
8
-2
EBAY
42
-2
HAL
48
-3
PG
50
2
URBN
48
-6
ORLY
60
-5
SJM
9
-5
F
56
-3
AMT
37
3
ED
45
3
EMR
71
-3
PBI
56
-2
CMG
66
-4
HCP
56
-8
SBUX
37
-2
MRO
50
4
TGNA
50
-6
DFS
64
2
ETN
75
-3
CHD
54
4
Financhill
Back

Protagonist Therapeutics Quote, Financials, Valuation and Earnings

Buy these stocks BEFORE President Trump returns to the Oval Office

See details on which stocks are poised to surge.
Sell
26

PTGX
Protagonist Therapeutics

Last Price:
41.14
Seasonality Move:
12.96%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump wins! Dow to 75,000? Details here

See the explosive "Document 20" details here.

Protagonist Therapeutics Price Quote

$41.14
+0.03 (+0.24%)
(Updated: November 16, 2024 at 5:34 AM ET)

Protagonist Therapeutics Key Stats

Sell
26
Protagonist Therapeutics (PTGX) is a Sell
Day range:
$39.41 - $41.84
52-week range:
$15.58 - $48.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.83
P/B ratio:
4.6%
Volume:
1.1M
Avg. volume:
544.4K
1-year change:
152.36%
Market cap:
$2.4B
Revenue:
$60M
EPS:
$2.66

How Much Does Protagonist Therapeutics Make?

Is Protagonist Therapeutics Growing As A Company?

Data Unavailable

Protagonist Therapeutics Stock Price Performance

What Is Protagonist Therapeutics 52-Week High & Low?

Protagonist Therapeutics Price To Free Cash Flow

Is It Risky To Buy Protagonist Therapeutics?

Is Protagonist Therapeutics Cash Flow Positive?

  • What Is PTGX Cash Flow From Operations?
    Cash flow from operations (TTM) is $230.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $22.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$352M

Protagonist Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PTGX return on invested capital is 37.59%
  • What Is Protagonist Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 33.69%
  • What Is PTGX Return On Equity?
    ROE is a measure of profitability and is 37.59%

Protagonist Therapeutics Earnings Date & Stock Price

Protagonist Therapeutics Competitors

Protagonist Therapeutics Dividend Yield

Protagonist Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.89%
Revenue: 0% 157.93%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 54.38
Upside from Last Price: 32.27%

Major Shareholders

  • How many PTGX shares are owned by institutional investors?
    109.5M PTGX shares are owned by institutional investors
  • How many PTGX shares are owned by insiders?
    1.1M PTGX shares are owned by insiders